Request for Public Comment: 30 Day Notice for Extension of Fast Track Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery: IHS Customer Service Satisfaction and Similar Surveys

CourtIndian Health Service
Citation87 FR 1764
Record Number2022-00364
Publication Date12 January 2022
1764
Federal Register / Vol. 87, No. 8 / Wednesday, January 12, 2022 / Notices
1
This refers to FDA’s Birth Control Guide
(https://www.fda.gov/media/150299/download) as
posted on December 22, 2021 with the exception of
sterilization surgery for men, which is beyond the
scope of the WPSI.
health insurance coverage are required
to cover specified preventive services
without a copayment, coinsurance,
deductible, or other cost sharing,
including preventive care and
screenings for women as provided for in
comprehensive guidelines supported by
HRSA for this purpose. Private health
insurance companies must provide this
coverage without cost-sharing in plan
years (in the individual market, policy
years) beginning on or after the date that
is one year after the date the
recommendation or guideline is issued.
A change to the Guidelines is
considered to be issued on the date on
which it is accepted by the HRSA
Administrator.
Summary of the 2021 Updates
Recommended by WPSI and Approved
by HRSA
Breastfeeding Services and Supplies
WPSI recommends comprehensive
lactation support services (including
consultation, counseling, education by
clinicians and peer support services,
and breastfeeding equipment and
supplies) during the antenatal,
perinatal, and postpartum periods to
optimize the successful initiation and
maintenance of breastfeeding.
Breastfeeding equipment and supplies
include, but are not limited to, double
electric breast pumps (including pump
parts and maintenance) and breast milk
storage supplies. Access to double
electric pumps should be a priority to
optimize breastfeeding and should not
be predicated on prior failure of a
manual pump. Breastfeeding equipment
may also include equipment and
supplies as clinically indicated to
support dyads with breastfeeding
difficulties and those who need
additional services.
Contraception
WPSI recommends that adolescent
and adult women have access to the full
range of contraceptives and
contraceptive care to prevent
unintended pregnancies and improve
health outcomes. Contraceptive care
includes screening, education,
counseling, and provision of
contraceptives (including in the
immediate postpartum period).
Contraceptive care also includes follow-
up care (e.g., management, evaluation,
and changes, including the removal,
continuation, and discontinuation of
contraceptives).
WPSI recommends that the full range
of U.S. Food and Drug Administration
(FDA)-approved, -granted, or -cleared
contraceptives, effective family
planning practices, and sterilization
procedures be available as part of
contraceptive care. The full range of
contraceptives currently includes those
listed in the FDA’s Birth Control
Guide:
1
(1) Sterilization surgery for
women, (2) implantable rods, (3) copper
intrauterine devices, (4) intrauterine
devices with progestin (all durations
and doses), (5) injectable contraceptives,
(6) oral contraceptives (combined pill),
(7) oral contraceptives (progestin only),
(8) oral contraceptives (extended or
continuous use), (9) the contraceptive
patch, (10) vaginal contraceptive rings,
(11) diaphragms, (12) contraceptive
sponges, (13) cervical caps, (14)
condoms, (15) spermicides, (16)
emergency contraception
(levonorgestrel), and (17) emergency
contraception (ulipristal acetate); and
any additional contraceptives approved,
granted, or cleared by the FDA.
Screening for HIV Infection
WPSI recommends all adolescent and
adult women, ages 15 and older, receive
a screening test for human
immunodeficiency virus (HIV) at least
once during their lifetime. Earlier or
additional screening should be based on
risk, and rescreening annually or more
often may be appropriate beginning at
age 13 for adolescent and adult women
with an increased risk of HIV infection.
WPSI recommends risk assessment
and prevention education for HIV
infection beginning at age 13 and
continuing as determined by risk.
A screening test for HIV is
recommended for all pregnant women
upon initiation of prenatal care with
rescreening during pregnancy based on
risk factors. Rapid HIV testing is
recommended for pregnant women who
present in labor with an undocumented
HIV status.
Counseling for Sexually Transmitted
Infections
WPSI recommends behavioral
counseling by a health care clinician or
other appropriately trained individual
for sexually active adolescent and adult
women at an increased risk for sexually
transmitted infections (STIs).
WPSI recommends that clinicians
review a woman’s sexual history and
risk factors to identify those at increased
risk for STIs. Risk factors include, but
are not limited to, age younger than 25
years, a recent history of an STI, a new
sex partner, multiple partners, a partner
with concurrent partners, a partner with
an STI, and a lack of or inconsistent
condom use. For those without
identified risk factors, counseling to
reduce the risk of STIs should be
considered on an individual basis as
determined by clinical judgment.
Well-Woman Preventive Visits
WPSI recommends that women
receive at least one preventive care visit
per year beginning in adolescence and
continuing across the lifespan to ensure
the provision of all recommended
preventive services. The primary
purpose of well-woman visits is the
delivery and coordination of
recommended preventive services as
determined by age and risk factors.
These services may be completed at a
single visit or as part of a series of visits
that take place over time to obtain all
necessary services depending on a
woman’s age, health status,
reproductive health needs, pregnancy
status, and risk factors. Well-women
visits also include pre-pregnancy,
prenatal, postpartum, and
interpregnancy visits.
Preventing Obesity in Midlife Women
WPSI recommends counseling midlife
women aged 40 to 60 years with normal
or overweight body mass index (BMI)
(18.5–29.9 kg/m2) to maintain weight or
limit weight gain to prevent obesity.
Counseling may include individualized
discussion of healthy eating and
physical activity.
Diana Espinosa,
Acting Administrator.
[FR Doc. 2022–00465 Filed 1–11–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Indian Health Service
Request for Public Comment: 30 Day
Notice for Extension of Fast Track
Generic Clearance for the Collection of
Qualitative Feedback on Agency
Service Delivery: IHS Customer
Service Satisfaction and Similar
Surveys
AGENCY
: Indian Health Service, HHS.
ACTION
: Notice and request for
comments. Request for extension of
approval.
SUMMARY
: In compliance with the
Paperwork Reduction Act of 1995, the
Indian Health Service (IHS) invites the
general public to take this opportunity
to comment on the information
collection Office of Management and
Budget (OMB) Control Number 0917–
0036, ‘‘Generic Clearance for the
VerDate Sep<11>2014 17:04 Jan 11, 2022 Jkt 256001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\12JAN1.SGM 12JAN1
lotter on DSK11XQN23PROD with NOTICES1
1765
Federal Register / Vol. 87, No. 8 / Wednesday, January 12, 2022 / Notices
Collection of Qualitative Feedback on
Agency Service Delivery.’’ This notice
announces our intent to submit this
previously approved information
collection, which expires January 31,
2022, to OMB for approval of an
extension and solicit comments on
specific aspects for the proposed
information collection.
DATES
: Consideration will be given to all
comments received by February 11,
2022.
Direct Your Comments To OMB: Send
your comments and suggestions
regarding the proposed information
collection contained in this notice,
especially regarding the estimated
public burden and associated response
time to: Office of Management and
Budget, Office of Regulatory Affairs,
New Executive Office Building, Room
10235, Washington, DC 20503,
Attention: Desk Officer for IHS.
FOR FURTHER INFORMATION CONTACT
: To
request additional information, please
contact Evonne Bennett, Information
Collection Clearance Officer at:
Evonne.Bennett@ihs.gov or 301–443–
4750.
SUPPLEMENTARY INFORMATION
: The IHS is
submitting the proposed information
collection to OMB for review, as
required by the Paperwork Reduction
Act of 1995, as amended, and its
implementing regulations. This notice is
soliciting comments from members of
the public and affected agencies as
required by 44 U.S.C. 3507 and 5 CFR
1320.10 concerning the proposed
collection of information to: (1) Evaluate
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information will have practical utility;
(2) Evaluate the accuracy of the agency’s
estimate of the burden of the proposed
collection of information; (3) Enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Minimize the burden of the collection of
information on those who are to
respond; including through the use of
appropriate automated collection
techniques of other forms of information
technology, e.g., permitting electronic
submission of responses.
Title: Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery: IHS Customer
Service Satisfaction and Similar
Surveys.
Type of Information Collection
Request: Three year extension approval
of this information collection.
OMB Control Number: 0917–0036.
Abstract: The proposed information
collection activity provides a means to
garner qualitative customer and
stakeholder feedback in an efficient,
timely manner, in accordance with the
Administration’s commitment to
improving service delivery. Qualitative
feedback is information that provides
useful insights on perceptions and
opinions, but is not statistical surveys
that yield quantitative results that can
be generalized to the population of
study. This feedback will provide
insights into customer or stakeholder
perceptions, experiences and
expectations, provide an early warning
of issues with service, or focus attention
on areas where communication, training
or changes in operations might improve
delivery of products or services. These
collections will allow for ongoing,
collaborative and actionable
communications between the Agency
and its customers and stakeholders. It
will also allow feedback to contribute
directly to the improvement of program
management.
The solicitation of feedback will target
areas such as: Timeliness,
appropriateness, accuracy of
information, courtesy, efficiency of
service delivery, and resolution of
issues with service delivery. Responses
will be assessed to plan and inform
efforts to improve or maintain the
quality of service offered to the public.
If this information is not collected, vital
feedback from customers and
stakeholders on the agency’s services
will be unavailable.
The agency will only submit a
collection for approval under this
generic clearance if it meets the
following conditions:
Information gathered will be used
only internally for general service
improvement and program management
purposes and is not intended for release
outside of the agency;
Information gathered will not be
used for the purpose of substantially
informing influential policy decisions;
Information gathered will yield
qualitative information; the collections
will not be designed or expected to
yield statistically reliable results or used
as though the results are generalizable to
the population of study;
The collections are voluntary;
The collections are low-burden for
respondents (based on considerations of
total burden hours, total number of
respondents, or burden-hours per
respondent) and are low-cost for both
the respondents and the Federal
Government;
The collections are non-
controversial and do not raise issues of
concern to other Federal agencies;
Any collection is targeted to the
solicitation of opinions from
respondents who have experience with
the program or may have experience
with the program in the near future; and
With the exception of information
needed to provide remuneration for
participants of focus groups and
cognitive laboratory studies, personally
identifiable information (PII) is
collected only to the extent necessary
and is not retained.
Feedback collected under this generic
clearance provides useful information,
but it does not yield data that can be
generalized to the overall population.
This type of generic clearance for
qualitative information will not be used
for quantitative information collections
that are designed to yield reliably
actionable results, such as monitoring
trends over time or documenting
program performance. Such data uses
require more rigorous designs that
address: The target population to which
generalizations will be made, the
sampling frame, the sample design
(including stratification and clustering),
the precision requirements or power
calculations that justify the proposed
sample size, the expected response rate,
methods for assessing potential non-
response bias, the protocols for data
collection, and any testing procedures
that were or will be undertaken prior to
fielding the study. Depending on the
degree of influence the results are likely
to have, such collections may still be
eligible for submission for other generic
mechanisms that are designed to yield
quantitative results.
As a general matter, information
collections will not result in any new
system of records containing privacy
information and will not ask questions
of a sensitive nature, such as sexual
behavior and attitudes, religious beliefs,
and other matters that are commonly
considered private.
Current Actions: Extension of
approval for a collection of information.
Type of Review: Extension.
Affected Public: Individuals and
households, businesses and
organizations, and Tribal governments.
Estimated Number of Respondents:
105,000.
Below are projected annual average
estimates for the next three years:
Average Expected Annual Number of
Activities: 100.
Average number of Respondents per
Activity: 1,050.
Annual responses: 105,000.
Frequency of Response: Once per
request.
Average minutes per response: 10.
Burden hours: 17,500.
There are no direct costs to
respondents to report.
An agency may not conduct or
sponsor, and a person is not required to
VerDate Sep<11>2014 17:04 Jan 11, 2022 Jkt 256001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\12JAN1.SGM 12JAN1
lotter on DSK11XQN23PROD with NOTICES1
1766
Federal Register / Vol. 87, No. 8 / Wednesday, January 12, 2022 / Notices
respond to, a collection of information
unless it displays a currently valid OMB
control number.
Comment Due Date: Your comments
regarding this information collection are
best assured of having full effect if
received within 30 days of the date of
this publication.
Elizabeth A. Fowler,
Acting Deputy Director, Indian Health
Service.
[FR Doc. 2022–00364 Filed 1–11–22; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; Non-
Pharmacological Clinical Trials.
Date: February 8, 2022.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Regina Tousignant Dolan-
Sewell, Division of Extramural Activities,
National Institute of Mental Health, NIH,
Neuroscience Center, 6001 Executive Blvd.,
Room 4154, MSC 9606, Bethesda, MD 20852,
regina.dolan-sewell@nih.gov
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Service Ready Tools for Suicide Prevention.
Date: February 11, 2022.
Time: 10:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Nicholas Gaiano, Ph.D.,
Review Branch Chief, Division of Extramural
Activities, National Institute of Mental
Health, NIH, Neuroscience Center/Room
6150/MSC 9606, 6001 Executive Boulevard,
Bethesda, MD 20892–9606, 301–443–2742,
nick.gaiano@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: January 6, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–00431 Filed 1–11–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Aging Special Emphasis Panel, February
14, 2022, 1:00 p.m. to 3:30p.m.,
National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Suite
2W200, Bethesda, MD 20892, which
was published in the Federal Register
on December 16, 2021, FR Doc 2021–
27280, 86 FR 71512.
The meeting notice is amended to
change the date of the meeting from
February 14, 2022 to February 24, 2022.
The meeting is closed to the public.
Dated: January 7, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–00483 Filed 1–11–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Acquired
Resistance to Therapy Network (ARTNet).
Date: February 16–17, 2022.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W124, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: David G. Ransom, Ph.D.,
Chief, Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W124,
Rockville, Maryland 20850, 240–276–6351,
david.ransom@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–9:
Contract Review Meeting.
Date: February 25, 2022.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W236, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Shuli Xia, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH 9609 Medical Center Drive,
Room 7W236 Rockville, Maryland 20850
240–276–5256 shuli.xia@nih.gov
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–4:
SBIR Contract Review Meeting.
Date: March 3–4, 2022.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W106, Rockville, Maryland 20850
(Telephone Conference Call),
Contact Person: Eduardo Emilio Chufan,
Ph.D., Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W106, Rockville, Maryland
20850, 240–276–7975, chufanee@
mail.nih.gov,
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–8:
Contract Review Meeting.
Date: March 4, 2022.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W236, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Shuli Xia, Ph.D., Scientific
Review Officer Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W236, Rockville, Maryland 20850,
240–276–5256 shuli.xia@nih.gov.
VerDate Sep<11>2014 17:04 Jan 11, 2022 Jkt 256001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 E:\FR\FM\12JAN1.SGM 12JAN1
lotter on DSK11XQN23PROD with NOTICES1

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT